{"schema_version":"secwatch.filing_event.v1","accession":"0000882095-21-000024","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2021-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.971239+00:00","generated_at":"2026-06-28T17:08:55.647880+00:00","sec_items":["2.02","9.01","8.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Gilead Q3 GAAP EPS $2.05, revenue $7.4B; Biktarvy record $2.3B; raises FY guidance; redeems $1B notes","bullets":["GAAP diluted EPS $2.05 vs $0.29 YoY; non-GAAP diluted EPS $2.65 vs $2.11 YoY.","Total Q3 revenue $7.4B (+13% YoY); product sales ex-Veklury $5.4B (-3% YoY).","Biktarvy sales record $2.3B (+20% YoY); Veklury sales $1.9B.","FY 2021 guidance raised: total product sales $26.0-26.3B; non-GAAP EPS $7.90-8.10.","Called $1B of 2023 notes (Floating Rate and 0.750% Senior Notes) for redemption on Nov 8, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0000882095-21-000024","json":"https://secwatch.observer/filing/0000882095-21-000024.json","markdown":"https://secwatch.observer/filing/0000882095-21-000024.md","text":"https://secwatch.observer/filing/0000882095-21-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000024/0000882095-21-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000024/gild-20211028.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T17:08:55.647880+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}